 Jackson Center, Pennsylvania--Newsfile Corp. - June 9, 2021 - Halberd Corporation OTC Pink: HALB commences experimentations to eradicate three of the principal components of Alzheimers Disease. By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the disease.Dr. Mitchell S. Felder, Halberd Corporations Chief Technical Officer and the inventor of Halberds technology, stated,... 